Saturday, July 11, 2026

pharma · Asthma · Multiple Sclerosis · TEVA

Teva Pharma

Teva Biotech is a pharma organization headquartered in TEL AVIV, DE. It trades on NYSE under ticker TEVA. Primary therapeutic focus areas include Asthma, Multiple Sclerosis, Pain, Crohn's Disease, Seasonal Allergic Rhini

10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV HQ
126 Employees
Public company Type
TEVA · NYSE Ticker
Company details
Clinical program

TEV-53275 Dose A

Phase 2 · small molecule · Asthma

TEV-53275 Dose A for Asthma is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

← All Teva Pharma GmbH projects Phase 2 small molecule terminated

Internal code TV53275-AS-20033

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Teva Pharma GmbH
Phase
Phase 2
Modality
small_molecule
Indication
Asthma
Status
terminated
Trials
1

Clinical trials